Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Aneurysm III: Interprofessional Care01:26

Aneurysm III: Interprofessional Care

352
Aneurysm management involves either conservative medical therapy or surgical intervention, depending on the size and symptoms of the aneurysm. Conservative management is generally reserved for smaller, asymptomatic aneurysms, while larger or symptomatic aneurysms often necessitate surgical repair.Conservative Medical TherapyFor small, asymptomatic aneurysms, particularly abdominal aortic aneurysms (AAA) less than 5.5 centimeters in diameter, conservative medical therapy is recommended. This...
352
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.0K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.0K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

473
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
473
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

603
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
603

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic biomarkers of clinical manifestations in giant cell arteritis define distinct patient subgroups.

Annals of the rheumatic diseases·2026
Same author

Identifying pre- and posttraumatic brain injury pathways with a multidomain sequence analysis: a retrospective cohort study.

Annals of physical and rehabilitation medicine·2026
Same author

A symposium update on the key perspectives in systemic sclerosis and systemic lupus erythematosus.

Journal of translational autoimmunity·2026
Same author

Clinical and Immunovirological Characteristics Associated with Cardiovascular Dysautonomia in Long COVID.

Journal of clinical medicine·2026
Same author

Subtype-specific mortality in idiopathic inflammatory myopathies: A hospital-based cohort.

Autoimmunity reviews·2026
Same author

French recommendations for the use of imaging in giant cell arteritis.

Joint bone spine·2026

Related Experiment Video

Updated: Feb 21, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.6K

Incremental Costs in Giant Cell Arteritis.

Michael Mounié1, Nadège Costa2, Laurent Sailler3

  • 1Centre Hospitalier Universitaire de Toulouse, UMR 1027 INSERM, and Université de Toulouse, Toulouse, France.

Arthritis Care & Research
|October 4, 2017
PubMed
Summary
This summary is machine-generated.

Giant cell arteritis (GCA) significantly increases healthcare costs, particularly in the first 18 months. Key cost drivers include medical procedures, hospital stays, and medications, informing future economic analyses.

More Related Videos

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.4K
Minimally Invasive Thumb-sized Pterional Craniotomy for Surgical Clip Ligation of Unruptured Anterior Circulation Aneurysms
11:58

Minimally Invasive Thumb-sized Pterional Craniotomy for Surgical Clip Ligation of Unruptured Anterior Circulation Aneurysms

Published on: August 11, 2015

16.5K

Related Experiment Videos

Last Updated: Feb 21, 2026

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
06:35

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

7.6K
Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase G6PI-Induced RA Mice

Published on: January 31, 2020

7.4K
Minimally Invasive Thumb-sized Pterional Craniotomy for Surgical Clip Ligation of Unruptured Anterior Circulation Aneurysms
11:58

Minimally Invasive Thumb-sized Pterional Craniotomy for Surgical Clip Ligation of Unruptured Anterior Circulation Aneurysms

Published on: August 11, 2015

16.5K

Area of Science:

  • Rheumatology
  • Health Economics
  • Epidemiology

Background:

  • Giant cell arteritis (GCA) is a systemic vasculitis affecting large arteries, primarily the aorta and its branches.
  • Understanding the economic burden of GCA is crucial for resource allocation and evaluating treatment strategies.

Purpose of the Study:

  • To assess and compare direct medical and nonmedical costs in GCA patients versus matched controls.
  • To identify the primary drivers of incremental costs associated with GCA.

Main Methods:

  • Population-based, retrospective cohort study utilizing the French National Health Insurance System database.
  • Cost analysis from the French health insurance perspective, including direct medical and nonmedical costs (2014 prices).
  • Longitudinal multivariate regression analyses (generalized estimating equations) to adjust for GCA's effect on costs over time.

Main Results:

  • Cumulative incremental costs for GCA patients were €6,406 (3 years) and €7,236 (5 years).
  • Significant incremental costs were observed within the first 18 months post-diagnosis.
  • Major cost drivers included paramedical procedures, inpatient stays, medication, and medical procedures.

Conclusions:

  • This study offers a precise 5-year cost assessment for GCA, valuable for future economic evaluations.
  • Findings provide essential data for cost-effectiveness analyses of novel, potentially expensive GCA therapies, such as biotherapies.